JNJ
Johnson & Johnson
$253.79
-1.77
(-0.69%)
Mkt Cap
611.61B
Volume
8,678,979
52W Range
184.66-281.07
Sector
Healthcare
Beta
0.23
EPS (TTM)
6.60 USD
P/E Ratio
38.48
Revenue (TTM)
99.33B USD
Rev Growth (5Y)
+2.3%
EPS Growth (5Y)
+11.5%
AlphaVal · Fair Value
What we estimate one share is worth
$154.42
Overvalued
strong signal
64.4% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B+
Stable Earnings Power
78.4 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.19B | 88.82B | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B |
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B |
| EPS | 11.03 | 5.84 | 13.88 | 6.83 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 |
| Free Cash Flow | 19.70B | 19.84B | 18.25B | 17.18B | 19.76B | 20.19B | 19.92B | 18.53B | 17.78B | 15.54B | 15.82B | 14.76B |
| FCF / Share | 8.11 | 8.24 | 7.20 | 6.58 | 7.52 | 7.67 | 7.57 | 6.96 | 6.63 | 5.74 | 5.74 | 5.30 |
| Operating CF | 24.53B | 24.27B | 22.79B | 21.19B | 23.41B | 23.54B | 23.42B | 22.20B | 21.06B | 18.77B | 19.28B | 18.47B |
| Total Assets | 199.21B | 180.10B | 167.56B | 187.38B | 182.02B | 174.89B | 157.73B | 152.95B | 157.30B | 141.21B | 133.41B | 130.36B |
| Total Debt | 47.93B | 36.63B | 29.33B | 39.64B | 33.75B | 35.27B | 27.70B | 30.48B | 34.58B | 27.13B | 19.86B | 18.76B |
| Cash & Equiv | 19.71B | 24.11B | 21.86B | 12.89B | 14.49B | 13.98B | 17.30B | 18.11B | 17.82B | 18.97B | 13.73B | 14.52B |
| Book Value | 81.54B | 71.49B | 68.77B | 76.80B | 74.02B | 63.28B | 59.47B | 59.75B | 60.16B | 70.42B | 71.15B | 69.75B |
| Return on Equity | 0.33 | 0.20 | 0.51 | 0.23 | 0.28 | 0.23 | 0.25 | 0.26 | 0.02 | 0.23 | 0.22 | 0.23 |
| Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.40B | 25.31B | 24.06B | 24.56B | 23.99B | 23.74B | 21.89B | 22.52B | 22.47B | 22.45B | 21.38B | 21.39B |
| Net Income | 210.00M | 5.53B | 5.24B | 5.12B | 5.15B | 5.54B | 11.00B | 3.43B | 2.69B | 4.69B | 3.25B | 4.05B |
| EPS | 0.09 | 2.27 | 2.14 | 2.10 | 2.14 | 2.29 | 4.57 | 1.43 | 1.12 | 1.95 | 1.35 | 1.68 |
| Free Cash Flow | N/A | 3.39B | 1.47B | 5.47B | 8.38B | 2.48B | 3.38B | 4.84B | 5.71B | 4.66B | 2.85B | 6.27B |
| FCF / Share | N/A | 1.39 | 0.60 | 2.25 | 3.45 | 1.03 | 1.40 | 2.01 | 2.37 | 1.93 | 1.18 | 2.61 |
| Operating CF | N/A | 4.71B | 2.51B | 7.31B | 9.17B | 3.88B | 4.17B | 6.98B | 7.99B | 5.63B | 3.66B | 7.86B |
| Total Assets | N/A | 201.06B | 200.89B | 199.21B | 192.82B | 193.39B | 193.67B | 180.10B | 178.29B | 181.09B | 171.97B | 167.56B |
| Total Debt | N/A | 49.04B | 54.99B | 47.93B | 45.80B | 50.76B | 52.25B | 36.63B | 35.75B | 41.49B | 33.63B | 29.33B |
| Cash & Equiv | N/A | 20.42B | 21.69B | 19.71B | 18.23B | 18.58B | 38.47B | 24.11B | 19.98B | 24.88B | 25.47B | 21.86B |
| Book Value | N/A | 84.97B | 81.19B | 81.54B | 79.28B | 78.47B | 78.11B | 71.49B | 70.16B | 71.54B | 70.02B | 68.77B |
| Return on Equity | N/A | 0.07 | 0.06 | 0.06 | 0.06 | 0.07 | 0.14 | 0.05 | 0.04 | 0.07 | 0.05 | 0.06 |
JNJ News
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys
Johnson & Johnson $JNJ Stock: AdvisorNet Financial Inc Increases Stake
Johnson & Johnson $JNJ Position Boosted by Assenagon Asset Management S.A.
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
The Stocks That Will Get Investors Home Safe When Tech Cracks
Glucose monitoring devices for type 2 diabetes benefit even those not on insulin